



# Tenet Health

38<sup>th</sup> Annual J.P. Morgan Healthcare Conference

---

Ronald Rittenmeyer, Executive Chairman and CEO

January 14, 2020



## FORWARD-LOOKING STATEMENTS

This presentation includes “forward-looking statements.” These statements relate to future events, including, but not limited to, statements regarding our future earnings, financial position, operational and strategic initiatives, and developments in the healthcare industry. These forward-looking statements represent management’s expectations, based on currently available information, as to the outcome and timing of future events, but, by their nature, address matters that are uncertain. Actual results, performance or achievements could differ materially from those expressed in any forward-looking statement.

Examples of uncertainties that may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements include, but are not limited to, the factors described under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2018, subsequent Form 10-Q filings and other filings with the Securities and Exchange Commission.

We assume no obligation to update any forward-looking statements or information subsequent to the dates such statements are made. Investors are cautioned not to place undue reliance on our forward-looking statements.

## NON-GAAP FINANCIAL INFORMATION

This presentation contains financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP). Reconciliations of these non-GAAP measures to the most comparable GAAP measures are included in our earnings press release dated November 4, 2019. Management’s reasoning for using these non-GAAP measures is also included in our earnings press release dated November 4, 2019.



Tenet Health Today

2019 – A Year in Review

Tenet Looking Forward

Enablers of Performance

# Tenet today – A leading health systems and services platform

65	Hospitals
296	Ambulatory Surgery Centers
107	Urgent Care Centers
77	Imaging Centers
24	Surgical Hospitals
26	Off-Campus EDs & Micro-Hospitals



~\$18B  
Revenue

10M  
Patient Encounters

~\$25B  
Revenue managed by Conifer

~50  
Health System Partners

110K  
Employees

Note: As of Jan 6, 2020.

# 2019 – A Year in Review

## Operations and Finance

### **Restored organic growth**

Consecutive quarters of growth. Same-facility hospital-based adjusted admissions grew +2.8% and ambulatory surgery cases grew +4.4% in Q3 over prior year

### **Continued to improve quality and patient experience**

Overall hospital scores for publically reported CMS quality measures increased, internal measures also demonstrate improvement in quality and experience

### **Achieved further operational efficiencies**

Cost savings program on track. \$300M of the \$450M target realized by end of 2019 via centralization, overhead reductions, off-shoring, external spend management


### **Improved financial flexibility**

Refinanced \$5.7B of debt. Expect to generate annual cash interest payment savings of \$18M, retired all significant debt maturities until April 2022; increased 1<sup>st</sup> Lien secured borrowing capacity from 3X to 4X EBITDA


Note: Please see company's Q3'19 earnings presentation dated Nov 4, 2019 for more details.

# Accelerating volume growth

## Hospital adjusted admissions growth



## Ambulatory surgical case growth




Note: Same-facility basis. Admissions adjusted by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing the results by gross inpatient revenues.

# Increasing Conifer earnings

Adjusted EBITDA, \$M




Adjusted EBITDA Margin




Note: 2019 Outlook as issued on November 4, 2019. Please see company's Q3'19 earnings presentation dated Nov 4, 2019 for more details.

# Sustaining growth in continuing operations

Adjusted diluted earnings per share



Adjusted EBITDA, \$B



Note: 2019E based on 2019 Outlook as issued on November 4, 2019. 2017-19E compounded average growth rate calculated using mid-point of company's 2019 outlook.

# 2019 – A Year in Review

## Talent and Governance

### **Enhanced physician complement**

Increased employed quality medical specialists and aligning with other leading medical groups in our markets that meet the need for quality services; implementing scheduling and OR improvements

### **Continued to invest in talent**

Transitioned additional leadership across corporate, hospital, ambulatory, and Conifer as well as improved talent development processes

### **Strengthened governance**

70% of the Board of Directors is new in the last two years and 80% is new since 2015

# Strengthened specialty medical groups



**ORTHOPEDIC & SPINE INSTITUTE**  
at St. Mary's Medical Center



**Biltmore Cardiology**  
*Abrazo Medical Group*



**EL PASO ORTHOPAEDIC  
SURGERY GROUP**  
*A PROVIDENCE Medical Partners Practice*



# Added external talent



**Paola Arbour**  
EVP, CIO



**Tom Arnst**  
CAO, Conifer



**Bertrand Dussert**  
VP, Recruitment



**Ernest Franklin, MD**  
Chief Medical Officer



**Carolyn Jackson**  
CEO, MA Market



**Jeff Jones**  
SVP, Conifer



**Owen Morris**  
CFO, USPI



**Deepali Narula**  
VP, Patient Services & Performance Improvement, Conifer



**Kelly Pool**  
VP, Total Rewards



**Marie Quintana**  
EVP, Communications & Chief Marketing Officer



**Bryan Rogers**  
CEO, OCLA Market



**Sharilee Smith**  
VP, Tax



**Jennifer Strickland**  
COO, TPR



**Todd Wyatt**  
CFO, Conifer

# Refreshed Board of Directors



Ronald A. Rittenmeyer  
Executive Chairman & CEO,  
Tenet Healthcare



J. Robert Kerrey  
Lead Director, Tenet  
Healthcare; Managing  
Director, Allen & Company;  
Former United States  
Senator



Lloyd J. Austin, III  
General, U.S. Army (Ret.)  
and Former Commander of  
U.S. Central Command



James L. Bierman  
Former President and CEO,  
Owens & Minor, Inc.



Richard Fisher  
Former President and CEO,  
Federal Reserve Bank of  
Dallas



Meghan M. Fitzgerald, DrPH  
Managing Partner, L1 Health LLC



Chris Lynch  
Former National Partner in  
Charge of the Financial  
Services division at KPMG,  
LLC



Richard Mark  
Chairman and President,  
Ameren Illinois Company



Tammy Romo  
Executive Vice President and  
Chief Financial Officer,  
Southwest Airlines Co.



Nadja West, M.D.  
Lieutenant General, U.S.  
Army (Ret.) and 44th  
Surgeon General of the U.S.  
Army



# Tenet Looking Forward

## Drive performance, focusing on free cash flow

Continue to implement a cost management agenda and instill a culture of data-driven management processes to improve EBITDA and free cash flow

## Optimize portfolio of assets

Building a leading specialty care platform to serve the growing community needs and evaluating each asset's role in the go-forward portfolio

## Scale ambulatory surgery business

Accelerate investments in USPI's strong pipeline via acquisitions to deliver benefits of scale as well as develop de novos to meet growing patient demand

## Prepare for Conifer spin


Improve capabilities and margin as well as continue actions to spin Conifer

# Increasing data-driven management processes


## Daily Volume Metrics



## Payor Mix & Yield



## Service Line



The figure consists of four separate screenshots from a business intelligence or expense management system, arranged in a grid-like fashion. The top-left screenshot shows a 'Total Cash (IP & OP)' report with columns for Actual, Budget, Var%, and Grt% for various categories like Total, IP, and OP. The top-right screenshot shows a 'Net Payroll' report for Service Line A, detailing figures for IP and OP across months from May 19 to Oct 19. The bottom-left screenshot shows an 'Expense Labor' report for Master Group 1, listing items like Travel, Lodging, and Food. The bottom-right screenshot shows a detailed breakdown of a travel expense for a trip to New York City, including dates, locations, and costs for airfare, hotel, and meals.


**FOR PRESENTATION PURPOSES**

**ILLUSTRATIVE EXPENSE MANAGEMENT**

## Access




## Quality & Safety




# Utilizing predictive and geospatial analytics

## Predictive, mid-month volume tracker



# Geospatial, sub-service and payor dashboard



**Multiple values**

	3,290	3,415	1,860	3,226	(-3.7%)	2.0%
	780	724	452	749	7.8%	4.2%
	2,342	2,316	1,331	2,267	111%	3.3%
	5,280	5,321	3,003	5,357	(-0.8%)	2.4%
	5,467	6,042	3,066	5,527	(9.5%)	(1.1%)
	398	336	233	320	19.5%	24.3%
	3,223	3,298	1,853	3,084	(-23%)	4.5%
	5,865	5,441	3,357	5,556	2.0%	5.6%
	3,311	3,567	1,875	3,409	(6.1%)	(1.7%)
	1,259	1,208	719	1,183	4.2%	6.5%

**MARKET**

**FACILITY**  
All

**PATIENT CLASS**  
All


**EMERGENT/ELECTIVE**  
All

**MEDICAL/SURGICAL**  
All

**PAYER GROUP**  
All

**SERVICE LINE**


# Strategic focus on care for those with chronic diseases



- Expand service lines with a focus on servicing the needs for chronic disease and aging patients
- Continue focus on high-quality physicians as well as access and service excellence
- Improve patient access via operational and scheduling improvements as well as transfer centers
- Continue to improve Quality & Safety and performance in value-based programs (e.g., BPCI-A)
- Align capital placement, with a greater focus on strategic capital and clinical equipment

# Prioritize capital to grow ambulatory surgery footprint

Market share by number facilities




- Build upon USPI's national platform to deliver benefits of scale to a fragmented market
- Sustain strong pipeline of opportunities for individual centers as well as multi-center platforms
- Expect to deploy \$150-\$175M annually, possibly more if the right opportunities are identified
- Purchase centers at attractive multiples and reduce the EBITDA less NCI multiple to below 5x by year two

Note: Other national providers include Envision, UnitedHealth, Surgery Partners, HCA and NueHealth  
Source: VMG Intellimarker, company filings

# Also investing in de novo ASCs and expanding service offerings

HOPD vs. ASC volume growth, % p.a.

Commercial Medicare FFS



- Continue strong pipeline of de novo opportunities to meet growing demand in existing and new markets
- Maintain strong trajectory of same-facility case growth across the ambulatory surgery portfolio
- Expand orthopedics, spine, cardiovascular and robotics services
- Sustain strong quality & safety, patient experience and physician engagement

# Evolving and globalizing the operating model

---




- Building upon integrated corporate functions to further streamline processes and improve services
- Continuous improvement in labor and external spend management with further standardization and automation
- Implementing a hybrid service delivery model with a Global Business Center (GBC) and outsource providers
- Selection for outsourcing versus GBC based on balancing strategy with capability, cost, risk, and timing


# Conifer today – inventing revenue cycle management

## Leveraging scale, expertise and advanced analytics

- Powered by Artificial Intelligence and mature predictive analytics to reduce friction and improve performance and patient experience
- Informed by real-time insights, data science and automated workflow that optimizes revenue cycle performance (e.g., denials prevention, coding and payer strategy)
- Automated to optimize quality, efficiency and performance in an ever changing environment
- Designed to provide consumers with a more a retail experience and greater financial transparency



# Preparing to spin Conifer



# Enablers of Performance

## A high-performance culture

Continue to add and cultivate talent, reduce silos, and align performance evaluation and talent development processes

## Fact-based driven decision making

Complement streamlined decision making processes with more rigorous business plans and data to inform decisions

## Action-oriented management processes

Utilize analytical insights to focus management processes on identifying root cause issues and problem solving potential solutions to address barriers



## MISSION

*To provide quality, compassionate care in the communities we serve.*

## VISION

*To consistently deliver the right care, in the right place, at the right time and to be a premier organization to work, where patient care and saving lives remain our focus.*

# Tenet Healthcare Corporation

## Additional Supplemental Non-GAAP disclosures

### Reconciliation of Outlook Net Income Available (Loss Attributable) to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted EBITDA

(Unaudited)

(Dollars in millions)

	<b>2019</b>	
	<b>Low</b>	<b>High</b>
<b>Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders</b>	\$ (220)	\$ (125)
Less: Net income available to noncontrolling interests	(390)	(410)
Net income (loss) from discontinued operations, net of tax	10	10
Income tax expense	(150)	(160)
Interest expense	(995)	(985)
Loss from early extinguishment of debt <sup>(1)</sup>	(227)	(227)
Other non-operating expense, net	(5)	(10)
Net losses on sales, consolidation and deconsolidation of facilities <sup>(1)</sup>	(3)	(3)
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements <sup>(2)</sup>	(275)	(250)
Depreciation and amortization	(830)	(840)
Loss from divested and closed businesses	(5)	—
<b>Adjusted EBITDA</b>	<b>\$ 2,650</b>	<b>\$ 2,750</b>
<b>Income (loss) from continuing operations</b>	<b>\$ (230)</b>	<b>\$ (135)</b>
<b>Net operating revenues</b>	<b>\$ 18,350</b>	<b>\$ 18,550</b>
<b>Income (loss) from continuing operations as a % of operating revenues</b>	<b>(1.3)%</b>	<b>(0.7)%</b>
<b>Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)</b>	<b>14.4 %</b>	<b>14.8 %</b>

- (1) The Company does not generally forecast losses from the early extinguishment of debt or net gains (losses) on sales, consolidation and deconsolidation of facilities because the Company does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook. The figures shown represent the Company's actual year-to-date results for these items.
- (2) The Company has provided an estimate of restructuring charges and related payments that it anticipates in 2019. The figures shown represent the Company's estimate for restructuring charges plus the actual year-to-date results for impairment charges, acquisition-related costs, and litigation costs and settlements. The Company does not generally forecast impairment charges, acquisition-related costs, litigation costs and settlements because the Company does not believe that it can forecast these items with sufficient accuracy since some of these items are indeterminable at the time the Company provides its financial Outlook.

# Tenet Healthcare Corporation

## Additional Supplemental Non-GAAP disclosures

**Reconciliations of Outlook Net Income Available (Loss Attributable) to Tenet Healthcare Corporation Common Shareholders to Outlook Adjusted Net Income Available from Continuing Operations to Common Shareholders**

(Unaudited)

(Dollars in millions except per share amounts)

	<b>2019</b>	
	<b>Low</b>	<b>High</b>
<b>Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders</b>	<b>\$ (220)</b>	<b>\$ (125)</b>
Net income (loss) from discontinued operations, net of tax	10	10
Net income (loss) from continuing operations	(230)	(135)
Less: Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements	(275)	(250)
Net losses on sales, consolidation and deconsolidation of facilities	(3)	(3)
Loss from early extinguishment of debt	(227)	(227)
Loss from divested and closed businesses	(5)	—
Tax impact of above items	40	35
Noncontrolling interests impact of above items	4	4
<b>Adjusted net income available from continuing operations to common shareholders</b>	<b>\$ 236</b>	<b>\$ 306</b>
<b>Diluted earnings (loss) per share from continuing operations</b>	<b>\$ (2.23)</b>	<b>\$ (1.31)</b>
Less: Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements	(2.62)	(2.38)
Net losses on sales, consolidation and deconsolidation of facilities	(0.03)	(0.03)
Loss from early extinguishment of debt	(2.16)	(2.16)
Loss from divested and closed businesses	(0.05)	—
Tax impact of above items	0.38	0.33
Noncontrolling interests impact of above items	0.04	0.04
<b>Adjusted diluted earnings per share from continuing operations</b>	<b>\$ 2.25</b>	<b>\$ 2.91</b>
<b>Weighted average basic shares outstanding (in thousands)</b>	<b>103,000</b>	<b>103,000</b>
<b>Weighted average dilutive shares outstanding (in thousands)</b>	<b>105,000</b>	<b>105,000</b>

# Tenet Healthcare Corporation

## Additional Supplemental Non-GAAP disclosures

### Reconciliations of Adjusted EBITDA to Net Income Available (Loss Attributable) to Tenet Healthcare Corporation Common Shareholders (Unaudited)

(Dollars in millions)	Years Ended December 31,	
	2017	2018
<b>Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders</b>	<b>\$ (704)</b>	<b>\$ 111</b>
Less: Net income attributable to <del>noncontrolling</del> interests	(384)	(355)
Income from discontinued operations, net of tax	—	3
Income (loss) from continuing operations	(320)	463
Income tax expense	(219)	(176)
Gain (loss) from early extinguishment of debt	(164)	1
Other non-operating expense, net	(22)	(5)
Interest expense	(1,028)	(1,004)
Operating income	1,113	1,647
Litigation and investigation costs	(23)	(38)
Gains on sales, consolidation and deconsolidation of facilities	144	127
Impairment and restructuring charges, and acquisition-related costs	(541)	(209)
Depreciation and amortization	(870)	(802)
Income (loss) from divested and closed businesses	(41)	9
<b>Adjusted EBITDA</b>	<b>\$ 2,444</b>	<b>\$ 2,560</b>
Net operating revenues	\$ 19,179	\$ 18,313
Less: Net operating revenues from health plans	110	14
<b>Adjusted net operating revenues</b>	<b>\$ 19,069</b>	<b>\$ 18,299</b>
Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders as a % of net operating	(3.7)%	0.6%
Adjusted EBITDA as % of adjusted net operating revenues (Adjusted EBITDA margin)	12.8 %	14.0%

# Tenet Healthcare Corporation

## Additional Supplemental Non-GAAP disclosures

**Reconciliations of Net Income Available (Loss Attributable) to  
Tenet Healthcare Corporation Common Shareholders to Adjusted Net Income Available (Loss  
Attributable) from Continuing Operations to Common Shareholders  
(Unaudited)**

(Dollars in millions except per share amounts)	Years Ended December 31,	
	2017	2018
<b>Net income available (loss attributable) to Tenet Healthcare Corporation common shareholders</b>	<b>\$ (704)</b>	<b>\$ 111</b>
Net income (loss) from discontinued operations	—	3
Net loss from continuing operations	(704)	108
Less: Impairment and restructuring charges, and acquisition-related costs	(541)	(209)
Litigation and investigation costs	(23)	(38)
Net gains on sales, consolidation and deconsolidation of facilities	144	127
Gain (loss) from early extinguishment of debt	(164)	1
Income (loss) from divested and closed businesses	(41)	9
Tax impact of above items	114	25
Tax reform adjustment	(252)	—
<b>Noncontrolling interests impact of above items</b>	<b>(23)</b>	<b>—</b>
<b>Adjusted net income available (loss attributable) from continuing operations to common shareholders</b>	<b>\$ 82</b>	<b>\$ 193</b>
<b>Diluted earnings (loss) per share from continuing operation</b>	<b>\$ (7.00)</b>	<b>\$ 1.04</b>
Less: Impairment and restructuring charges, and acquisition-related costs	(5.34)	(2.01)
Litigation and investigation costs	(0.23)	(0.37)
Net gains on sales, consolidation and deconsolidation of facilities	1.42	1.22
Gain (loss) from early extinguishment of debt	(1.62)	0.01
Income (loss) from divested and closed businesses	(0.40)	0.09
Tax impact of above items	1.12	0.24
Tax reform adjustment	(2.49)	—
<b>Noncontrolling interests impact of above items</b>	<b>(0.23)</b>	<b>—</b>
<b>Adjusted diluted earnings (loss) per share from continuing operations</b>	<b>\$ 0.81</b>	<b>\$ 1.86</b>
<b>Weighted average basic shares outstanding (in thousands)</b>	<b>100,592</b>	<b>102,110</b>
<b>Weighted average dilutive shares outstanding (in thousands)</b>	<b>101,380</b>	<b>103,881</b>